4CORDEIRO P G. Breast reconstruction after surgery for breast cancer[ J ]. N Engl J Med ,2008,359 ( 15 ) : 1590-1601.
5SPEAR S L, SPITTLER C J. Breast reconstruction with implants and expanders[ J]. Plast Reconstr Surg,2001,107 ( 1 ) :177-187.
6BREUING K H, COLWELL A S. Inferolateral AlloDerm hammock for implant coverage in breast reconstruction [ J ]. Ann Plast Surg, 2007,59 ( 3 ) :250-255.
7SALGARELLO M, BARONE-ADESI L, TERRIBILE D, et al. Update on one-stage immediate breast reconstruction with definitive prosthesis after sparing mastectomies [ J ]. Breast ,2011,20 ( 1 ) :7-14.
8HOLLE J, PIERINI A. Breast reconstruction with an external ob- lique abdominis muscle turnover flap and a bipedicled abdominal skin flap[ J]. Plast Reconstr Surg, 1984,73 (3) :469-473.
9NAVA M B, CORTINOVIS U, OTTOLENGHI J, et al. Skin-reduc- ing mastectomy [ J ]. Plast Reconstr Surg, 2006, 118 ( 3 ) : 603-610.
10SAINT-CYR M, NAGARKAR P, WONG C, et al. The pedicled subpectoral fascia flap for expander coverage in postmastectomy breast reconstruction: a novel technique [ J ]. Plast Reconstr Surg, 2010,125 (5) :1328-1334.
3Mamounas EP. NRG Oncology/NSABP B-51/RTOG 1304: Phase m trial to determine if chest wall and regional nodal radiotherapy(CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce inva- sive cancer events in patients (pts) with positive axillary (Ax) nodes who are ypN0 after neoadjuvant chemotherapy ( NC ) [C ]. J Clin Oncol, 2015, 33(TPSl1112).
4Chagpar AB. Can routine cavity shave margins (CSM) improve lo- cal control in breast cancer Initial results of the SHAVE trial, a prospective randomized controlled trial of routine CSM vs. standard partial mastectomy (SPM) [ C]. J Clin Oncol, 2015, 33 (1012).
5Marco Colleoni. Low-dose oral cyclophosphamide-me~lotrexate maintenance (CMM) for receptor-negative early breast cancer (BC) [CI. J Clin Oncol, 2015, 53(1002).
6Rosenberg M. Ovarian function suppression, symptom burden, and quality of life in young women with breast cancer: A prospective study[C]. J Clin Oneol, 2015, 33(515).
7Paul Anthony Ellis. Phase 11, randomized study of trastuzumab emtansine ( T-DM1 )-pertuzumab ( P ) vs trastuzumab-taxane(HT) for first-line treatment of HER2-positive MBC : Primary re- suits from the MARIANNE study[ C]. J Clin Oncol, 2015, 33 (507).
8Barrios CH. Safety of trastuzumab emtansine (T-DM1) in 373 pa- tients 65 years or older with HER2-positive advanced breast canc- er: A subgroup analysis of the Kamilla study [ C ]. J Clin Oncol, 2015, 33(603).
9Turner NC. PALOMA3 : A double-blind, phase IH trial of fulves- trant with or without palbociclib in pre- and post-menopausal women with hormone receptorpositive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy [ C 1. J Clin Oncol, 2015, 33(LBA502).
10Slamon DJ. Long-term safety profile of palbociclib (P) in combi- nation with letrozole (L) as first-line treatment for postmenopausal patients with ER and HER2- advanced breast cancer (ABC) (PALOMA-1/TRIO-18[ C]. J Clin Oncol, 2015, 33(570).
